Related Experiment Video
Updated: Jul 13, 2026
12:45
Benefits of Cardiac Resynchronization Therapy in an Asynchronous Heart Failure Model Induced by Left Bundle Branch Ablation and Rapid Pacing
Published on: December 11, 2017
[Electrotherapy of cardiac failure]
1Klinik für Kardiologie und internistische Intensivmedizin, Städtische Kliniken Bielefeld,Lehrkrankenhaus der Westfälischen Wilhelms-Universität Münster, Teutoburger Strasse 50, 33604, Bielefeld, Deutschland. christoph.stellbrink@sk-bielefeld.de
Der Internist
|August 21, 2007
Summary
Cardiac resynchronization therapy (CRT) improves heart failure outcomes by correcting conduction disturbances like left bundle branch block (LBBB). While effective, patient selection and device choices require further research.
Area of Science:
- Cardiology
- Electrophysiology
Context:
- Intracardiac conduction disturbances, particularly left bundle branch block (LBBB), are prevalent in heart failure.
- LBBB signifies disease progression and impairs cardiac hemodynamics due to dyssynchronous contraction.
Purpose:
- To evaluate the efficacy of Cardiac Resynchronization Therapy (CRT) in managing heart failure patients with conduction disturbances.
- To address unresolved questions regarding CRT, including non-responder identification and optimal device selection.
Summary:
- CRT mitigates negative effects of LBBB, improving hemodynamics, exercise tolerance, and reducing ventricular volumes and mitral regurgitation.
- Major trials like CARE-HF and COMPANION show CRT reduces mortality, leading to its guideline adoption.
- Unanswered questions persist regarding CRT in specific patient groups (atrial fibrillation, narrow QRS, mild HF) and the necessity of defibrillator capabilities.
Impact:
- CRT offers significant benefits for heart failure patients with LBBB, improving clinical outcomes and survival.
- Further research is crucial to optimize CRT patient selection and device strategies for improved therapeutic success.
- Guideline recommendations support CRT, but personalized approaches are needed for non-responders and specific comorbidities.
Related Concept Videos
01:22Heart Failure VI: Adjunct Therapies
Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
01:26Heart Failure Drugs: Inotropic Agents
Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
01:30Electroconvulsive Therapy
Electroconvulsive therapy (ECT), or shock therapy, remains a critical biomedical intervention for severe, treatment-resistant depression. While its origins can be traced back to Hippocrates' observations that malaria-induced convulsions alleviated mental illness, modern ECT has evolved significantly from its earlier, more primitive applications. First introduced in 1938 by Ugo Cerletti and his colleagues, ECT involves inducing controlled seizures using electrical currents. In its early years,...
01:25Cardiopulmonary Resuscitation IV: Pharmacological Management
Pharmacologic intervention is crucial in treating cardiac arrest patients during ACLS or Advanced Cardiovascular Life Support. The ACLS algorithms guide the administration of specific drugs based on the patient's cardiac arrest rhythm, which includes pulseless ventricular tachycardia (VT), ventricular fibrillation (VF), asystole, and pulseless electrical activity (PEA).EpinephrineIndication: Epinephrine is the first-line drug for all cardiac arrest rhythms.Mechanism of Action: Epinephrine...
01:30Heart Failure V: Medical Management
Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
01:30Cardiomyopathy II: Dilated Cardiomyopathy
Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...